On Thursday evening, the US Food and Drug Administration (FDA) ruled that a biosimilar drug is interchangeable with the original. It is the first time ever that the agency has done this.
For patients using Sanofi's long-acting insulin Lantus, this means that they will now be able to get Mylan's product Semglee from their pharmacist, without having a doctor's prescription for that specific drug.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.